| Symbol | ELDN |
|---|---|
| Name | ELEDON PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 19800 MACARTHUR BLVD.,SUITE 250, IRVINE, California, 92612, United States |
| Telephone | +1 949 238-8090 |
| Fax | — |
| — | |
| Website | https://www.eledon.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001404281 |
| Description | Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The companys lead compound in development is AT-1501 which is the next generation anti-CD40L antibody. Additional info from NASDAQ: |
New Form S-3 - Eledon Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-01 <b>AccNo:</b> 0001193125-26-201426 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Eledon Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-197775 <b>Size:</b> 3 MB
Read moreNew Form ARS - Eledon Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-197765 <b>Size:</b> 2 MB
Read moreNew Form DEF 14A - Eledon Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-197732 <b>Size:</b> 6 MB
Read moreNew Form SCHEDULE 13G/A - Eledon Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-001125 <b>Size:</b> 7 KB
Read moreEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
Read more(19% Negative) ELEDON PHARMACEUTICALS, INC. (ELDN) Reports Q1 2026 Financial Results
Read moreNew Form 10-K - Eledon Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-19 <b>AccNo:</b> 0001193125-26-116164 <b>Size:</b> 17 MB
Read moreEledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
Read moreEledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06972069 | Tolerance Through Mixed Chimerism (Sip-Tego) | Early_Phase1 | Kidney Failure | Recruiting | 2025-05-31 | 2030-12-31 | ClinicalTrials.gov |
| NCT06305286 | Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibo… | Phase1 | Type 1 Diabetes Mellitus | Recruiting | 2024-03-04 | 2029-03-01 | ClinicalTrials.gov |
| NCT06126380 | Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients | Phase2 | Kidney Transplant Rejection | Enrolling_By_Invitation | 2023-10-25 | 2029-12-01 | ClinicalTrials.gov |
| NCT05983770 | Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation | Phase2 | Kidney Transplant Rejection | Completed | 2023-08-30 | 2025-09-25 | ClinicalTrials.gov |
| NCT05480657 | Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combinat… | Phase1 | Brittle Type 1 Diabetes Mellitus | Withdrawn | 2022-09-30 | 2028-08-01 | ClinicalTrials.gov |
| NCT05125068 | Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) | Phase2 | IgA Nephropathy | Terminated | 2022-03-21 | 2023-07-31 | ClinicalTrials.gov |
| NCT05027906 | Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney… | Phase1 | Prevention of Rejection in Kidney Transplant | Recruiting | 2022-02-18 | 2027-01-01 | ClinicalTrials.gov |
| NCT02687815 | Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma) | Phase2 | Asthma | Terminated | 2016-02-22 | 2019-09-17 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Asthma | TERMINATED | NCT02687815 |
| vitamin D3 4000 IU | Other | Phase PHASE2 | Asthma | TERMINATED | NCT02687815 |
| Placebo | Other | Phase PHASE2 | Asthma | TERMINATED | NCT02687815 |
| vitamin D3 4000 IU | Other | Phase PHASE2 | Asthma | TERMINATED | NCT02687815 |
| Isolated cadaveric islet cells | Other | Phase PHASE1 | Brittle Type 1 Diabetes Mellitus | WITHDRAWN | NCT05480657 |
| AT-1501 IV Infusion | Other | Phase PHASE1 | Brittle Type 1 Diabetes Mellitus | WITHDRAWN | NCT05480657 |
| AT-1501 | Other | Phase PHASE2 | IgA Nephropathy | TERMINATED | NCT05125068 |
| AT-1501 | Other | Phase PHASE1 | Prevention of Rejection in Kidney Transplant | RECRUITING | NCT05027906 |
| Tacrolimus | Other | Phase PHASE2 | Kidney Transplant Rejection | COMPLETED | NCT05983770 |
| AT-1501 | Other | Phase PHASE2 | Kidney Transplant Rejection | COMPLETED | NCT05983770 |
| Conditioning Regimen (Rituxan, Siplizumab, Cyclophosphamide, Tegoprubart) | Other | Phase EARLY_PHASE1 | Kidney Failure | RECRUITING | NCT06972069 |
| Donation of Kidney / Bone Marrow | Other | Phase EARLY_PHASE1 | Kidney Failure | RECRUITING | NCT06972069 |
| Combined Kidney/Bone Marrow Transplant | Other | Phase EARLY_PHASE1 | Kidney Failure | RECRUITING | NCT06972069 |
| Tacrolimus | Other | Phase PHASE2 | Kidney Transplant Rejection | ENROLLING_BY_INVITATION | NCT06126380 |
| AT-1501 | Other | Phase PHASE2 | Kidney Transplant Rejection | ENROLLING_BY_INVITATION | NCT06126380 |
| Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy | Drug | Phase PHASE1 | Type 1 Diabetes Mellitus | RECRUITING | NCT06305286 |
| Rejuveinix High Dose | DRUG | Phase PHASE1 | Critical Limb Ischemia | UNKNOWN | NCT03041259 |
| Rejuveinix Low Dose | DRUG | Phase PHASE1 | Critical Limb Ischemia | UNKNOWN | NCT03041259 |
| Placebo Comparator | DRUG | Phase PHASE1 | COVID-19 | UNKNOWN | NCT04708340 |
| Rejuveinix (RJX) Active Comparator | DRUG | Phase PHASE1 | COVID-19 | UNKNOWN | NCT04708340 |